This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gorrin, G.
Right arrow Articles by Comanor, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gorrin, G.
Right arrow Articles by Comanor, L.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, January 2003, p. 310-317, Vol. 41, No. 1
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.1.310-317.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Performance Evaluation of the VERSANT HCV RNA Qualitative Assay by Using Transcription-Mediated Amplification

Gregg Gorrin,1 Michel Friesenhahn,1 Patsy Lin,1 Marla Sanders,2 Reinhold Pollner,2 Brandon Eguchi,2 Jimmykim Pham,2 Gianluca Roma,2 Joseph Spidle,2 Susann Nicol,1 Carol Wong,1 Suvarna Bhade,1 and Lorraine Comanor3*

Bayer Corporation, Berkeley,1 Gen-Probe Incorporated, San Diego,2 Clinical Research Consultant, Palo Alto, California3

Received 20 June 2002/ Returned for modification 8 August 2002/ Accepted 17 October 2002

A preclinical evaluation of a qualitative assay for the detection of hepatitis C virus (HCV) RNA by transcription-mediated amplification (TMA) was conducted according to the guidelines of the National Committee for Clinical Laboratory Standards and the U.S. Food and Drug Administration. Our results showed that this assay, HCV TMA, detected 95% of samples with HCV RNA concentrations of 5.3 IU/ml and 29 copies/ml. HCV TMA showed an overall specificity of 99.6% and was highly reproducible, detecting 99.3% of samples with HCV RNA concentrations of 50 copies/ml across seven different lots of reagents. Experiments with clinical samples showed that HCV TMA detected all HCV genotypes with similar efficiencies, detecting >=95% of samples at 50 HCV RNA copies/ml from patients infected with HCV genotypes 1a, 2b, 3a, 4a, 5a, and 6a. In experiments with RNA transcripts, HCV TMA detected >=96.6% of transcripts derived from HCV genotypes 1a, 1b, 2a, 2c, 3a, 4a, 5a, and 6a at 50 HCV RNA copies/ml. Detection of transcripts derived from HCV genotype 2b was slightly lower (88.4%) at 50 copies/ml but was 97.0% at 75 copies/ml. In addition, HCV TMA exhibited robust performance in detecting HCV RNA in samples subjected to various conditions commonly encountered in a clinical laboratory, including long-term storage, multiple freeze-thaw cycles, different collection tubes, and the presence of endogenous substances, commonly prescribed drugs, or other microorganisms and viruses. With its high sensitivity, specificity, reproducibility, and equivalent genotype reactivity, HCV TMA may provide an attractive alternative for routine qualitative HCV RNA testing in clinical laboratories.

* Corresponding author. Mailing address: 1801 Waverley St., Palo Alto, CA 94301. Phone: (650) 321-8871. Fax: (650) 321-8872. E-mail: lorraine.comanor.b{at}bayer.com.

Journal of Clinical Microbiology, January 2003, p. 310-317, Vol. 41, No. 1
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.1.310-317.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Desombere, I., Van Vlierberghe, H., Couvent, S., Clinckspoor, F., Leroux-Roels, G. (2005). Comparison of Qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and Quantitative (COBAS AMPLICOR HCV Monitor 2.0 versus VERSANT HCV RNA 3.0) Assays for Hepatitis C Virus (HCV) RNA Detection and Quantification: Impact on Diagnosis and Treatment of HCV Infections. J. Clin. Microbiol. 43: 2590-2597 [Abstract] [Full Text]  
  • Krajden, M., Shivji, R., Gunadasa, K., Mak, A., McNabb, G., Friesenhahn, M., Hendricks, D., Comanor, L. (2004). Evaluation of the Core Antigen Assay as a Second-Line Supplemental Test for Diagnosis of Active Hepatitis C Virus Infection. J. Clin. Microbiol. 42: 4054-4059 [Abstract] [Full Text]  
  • Hendricks, D. A., Friesenhahn, M., Tanimoto, L., Goergen, B., Dodge, D., Comanor, L. (2003). Multicenter Evaluation of the VERSANT HCV RNA Qualitative Assay for Detection of Hepatitis C Virus RNA. J. Clin. Microbiol. 41: 651-656 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»